Article

Mobilization of Peripheral Blood Stem Cells Using Regimen Combining Docetaxel with Granulocyte Colony-stimulating Factor in Breast Cancer Patients.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing 100142, China.
Chinese Journal of Cancer Research (Impact Factor: 0.45). 03/2011; 23(1):49-53. DOI: 10.1007/s11670-011-0049-8
Source: PubMed

ABSTRACT To evaluate the effectiveness and safety of the mobilization of peripheral blood hematopoietic stem cells by combining docetaxel with granulocyte colony-stimulating factor (G-CSF) in breast cancer patients.
A total of 57 breast cancer patients were treated with docetaxel 120 mg/m. When the white blood cell (WBC) count decreased to 1.0×10/L, patients were given G-CSF 5 μg/kg daily by subcutaneous injection until the end of apheresis. Peripheral blood mononuclear cells (MNC) were isolated by Cobe Spectra Apheresis System. The percentage of CD34 cell was assayed by flow cytometry.
At a median 6 of days (range 3-8) after the administration of docetaxel, the median WBC count decreased to 1.08×10/L (range 0.20-2.31). The median duration of G-CSF mobilization was 3 days (range 2-7). The MNC collection was conducted 8-12 days (median 10 days) after docetaxel treatment. The median MNC was 5.35×10/kg (range 0.59-14.07), the median CD34 cell count was 2.43×10/kg (range 0.16-16.69). The CD34 cell count was higher than 1.00×10/kg in 47 of 57 cases (82.46%) and higher than 2.00×10/kg in 36 cases (63.16%). The CD34 cell count was higher than 2.00×10/kg in 27 collections (23.68%). The MNC count and the CD34 cell count were correlated with the bottom of WBC after docetaxel chemotherapy (r=0.364, 0.502, =0.005, 0.000). The CD34 cell count was correlated with the MNC count (r=0.597, =0.000). The mobilization and apheresis were well tolerated in all patients. Mild perioral numbness and numbness of hand or feet were observed in 3 cases. No serious adverse events were reported.
Mobilization of peripheral blood hematopoietic stem cell by combining docetaxel with G-CSF was effective and safety in breast cancer patients.

0 Bookmarks
 · 
51 Views